4-1BB: A promising target for cancer immunotherapy
Immunotherapy, powered by its relative efficacy and safety, has become a prominent therapeutic strategy utilized in the treatment of a wide range of diseases, including cancer. Within this class of therapeutics, there is a variety of drug types such as immune checkpoint blockade therapies, vaccines,...
Main Authors: | Alyssa Min Jung Kim, Macy Rose Nemeth, Seung-Oe Lim |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.968360/full |
Similar Items
-
Accelerating Cancer Immunotherapy Through 4-1BB Activation
by: Todd eBartkowiak, et al.
Published: (2015-06-01) -
An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
by: Dinh-Toi Chu, et al.
Published: (2019-04-01) -
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
by: Christina Claus, et al.
Published: (2023-12-01) -
A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity
by: Lian-sheng Cheng, et al.
Published: (2022-09-01) -
CD137<sup>+</sup> T-Cells: Protagonists of the Immunotherapy Revolution
by: Alessio Ugolini, et al.
Published: (2021-01-01)